INTRODUCTION
Fourth-generation cephalosporins represent a valuable addition to the therapeutic armamentarium since they have demonstrated activity against Gram-negative bacilli, including Enterobacteriaceae and, as well as Gram-positive cocci such as Streptococcus pneumoniae and methicllin-suceptible staphylococci. However, the lack of activity against methicillin-resistant staphylococci and extended-spectrum beta-lactamases (ESBL)-producing isolates has limited wider clinical use. 1, 2 According to the most recent SENTRY data report, Staphylococcus aureus (20.2%) and coagulase-negative staphylococci (CoNS; 14.5%) ranked as the first and second cause of bloodstream infections in Brazilian hospitals between 2005 and 2008. 3 S. aureus was also the most common cause of skin and soft tissue infections (28.1%) and was isolated from 24.9% of patients with pneumonia. In that study, 31.0% and 78.7% of S. aureus and CoNS showed resistance to methicillin. The limited number of approved drugs with activity against multidrug-resistant bacteria such as methicillin-resistant S. aureus (MRSA) has increased the demand for new agents with a novel mechanism of action or an ability to overcome bacterial resistance.
Ceftobiprole is a pyrrolidinone-3-ylidenemethyl cephalosporin with a broad-spectrum of activity against Gram-positive cocci and Gram-negative bacilli. [4] [5] [6] The binding of ceftobiprole to penicillin-binding proteins (PBPs) is a critical determinant of its antibacterial activity. 4 Ceftobiprole demonstrated potent binding to PBPs from Gram-positive bacteria, including those with decreased β-lactam sensitivity, such as PBP2a in MRSA and PBP2x in penicillin-resistant S. pneumoniae (PRSP), in contrast to ceftriaxone. In Escherichia coli, ceftobiprole exhibited strong binding to the essential PBPs, PBP2 and PBP3. It also exhibited a binding profile similar to those of cefepime and ceftazidime in P. aeruginosa but with enhanced binding to PBP2. These binding profiles explain the broad-spectrum activity for ceftobiprole. 5 In addition, in single-step and serial passage in vitro resistance development studies, ceftobiprole demonstrated a low propensity to select for resistant subpopulations. 7, 8 The purpose of this study was to assess the in vitro activity of ceftobiprole and comparator agents against Gram-positive cocci and Gram-negative bacilli, recently isolated from patients of Brazilian private hospitals.
MATERIAL AND METHODS

Participant medical centers
Four private hospitals participated of the INVITA-A-CEFTO Brazilian Study. The medical centers were located in four distinct Brazilian cities, Belo Horizonte, São Paulo, Rio de Janeiro and São Luís. Selection of the participant medical centers was based on the criteria that they should have preferentially ≥ 200 beds, at least one adult intensive care unit and located in cities with more than one million inhabitants.
Bacterial isolates
A total of 336 consecutive isolates of Gram-positive cocci and Gram-negative bacilli was submitted between February 2008 and August 2009. Each medical center was guided by protocol to submit Gram-positive cocci and Gramnegative bacilli collected from patients with diagnosis of pneumonia (40 isolates being from 20 ventilator-assisted patients), bloodstream infections (40 isolates) and skin and soft-tissue infections (20 isolates), according to the Centers for Disease Control and Prevention (CDC) definitions. 9 One isolate per patient was evaluated. All isolates were identified at the participating institution by routine methodologies in use at each laboratory. Upon receipt at the central laboratory (UNIFESP, São Paulo), isolates were subcultured to ensure viability and purity. Confirmation of species identification was performed with the BD Phoenix ™ Automated Microbiology System (BD Diagnostics, MD, USA) or conventional methods, as required. Table 2 . Antimicrobial activity of the tested agents and the susceptibility profile of the most frequent Gram-negative isolates are shown in Table 3 . Ceftobiprole showed similar activity to that displayed by cefepime against P. aeruginosa, K. pneumoniae, A. baumannii, E. coli and Enterobacter spp.
Susceptibility testing
P. aeruginosa showed the highest rates of susceptibility towards polymyxin B (98.9%), amikacin (59.1%) and piperacillin/tazobactam (58.1%) ( Table 3) . Among the cephalosporins, slightly greater percentage of isolates was inhibited at MICs ≤ 8 μg/mL by ceftazidime (48.4%) or cefepime (47.8%) than by ceftobiprole (36.8%). Ceftobiprole and ceftriaxone inhibited 36.8% of K. pneumoniae isolates at concentrations ≤ 8 μg/mL. Against this species, ceftobiprole activity was comparable to that displayed by cefepime (39.5%), but lower than that of ceftazidime (44.7%, Table 4 ). Among the carbapenems, meropenem (76.3% susceptibility) and doripenem (73.7% susceptibility) showed remarkable susceptibility rates, followed by imipenem (68.4% susceptibility). Moreover, imipenem (MIC 90 , 4 μg/mL) was two-fold more potent than meropenem (MIC 90 , 8 μg/mL) and doripenem (MIC 90 , 8 μg/mL) against K. pneumoniae isolates. All tested K. pneumoniae isolates were susceptible to tigecycline. Levofloxacin resistance was observed in 47.4% of K. pneumoniae isolates.
All tested A. baumannii isolates were susceptible to tigecycline (MIC 90 , 0.5 μg/mL) and polymyxin B (MIC 90 , ≤ 0.5 μg/mL). Ceftobiprole had MIC 50/90 , > 6 μg/mL as did cefepime and ceftazidime.
The potency of ceftobiprole (MIC 50 , 0.5 μg/mL) was identical to those displayed by ceftazidime (MIC 50 , 0.5 μg/mL) and cefepime (MIC 50 , 0.5 μg/mL) among E. coli isolates. Against Enterobacter spp., cefepime (MIC 50 , ≤ 0.12 μg/mL) was at least two-fold and four-fold more active than ceftobiprole (MIC 50 , 0.25 μg/mL) and ceftazidime (MIC 50 , 0.5 μg/mL), respectively. Nevertheless, the highest in vitro activity for ceftobiprole was observed for this genus. Approximately 68% and 76% of E. coli and Enterobacter spp., respectively, were inhibited by ceftobiprole at 8 μg/mL ( Table 4) .
The activity of ceftobiprole and other antimicrobial agents tested against Gram-positive isolates is shown in Tables 5 and 6 . Overall, 33.3% of S. aureus isolates were resistant to oxacillin. Ceftobiprole was two-fold more potent against oxacillin-susceptible S. aureus (MIC 50 , 0.5 μg/mL) than oxacillin-resistant S. aureus (MIC 50 , 1 μg/mL). All S. aureus strains were inhibited by concentrations of ceftobiprole ≤ 4 μg/mL. Agents providing the highest coverage against all S. aureus included vancomycin (MIC 50 , 1 μg/mL; 100% susceptible), teicoplanin (MIC 50 , ≤ 2 μg/mL; 100% susceptible), linezolid (MIC 50 , 4 μg/mL; 97.2% susceptible) and tigecycline (MIC 50 , 0.25 μg/mL; 97.2% susceptible). Tigecycline (MIC 50 , 0.25 μg/mL; 100% susceptibility) followed by ceftobiprole (MIC 50/90 , 1 and 8 μg/mL) were the most active agents tested against CoNS isolates. At 2 μg/mL, ceftobiprole inhibited 95.7% of CoNS isolates (Table 6) . Only a single CoNS isolate showed a ceftobiprole MIC of 8 μg/mL.
Ceftobiprole (MIC 50/90 , 0.5 and 16 μg/mL) inhibited the growth of 88.9% of the E. faecalis isolates at concentrations (Table 5) . One linezolid-resistant E. faecalis isolate (5.6%) was isolated from a patient diagnosed with skin and soft tissue infection.
DISCUSSION
The aim of this study was to assess the activity of ceftobiprole, a new broad-spectrum cephalosporin, against contemporary Gram-positive and Gram-negative pathogens collected from patients hospitalized at four distinct Brazilian medical centers, as part of the INVITA-A-CEFTO Brazilian Study. Ceftobiprole was highly potent against all staphylococcal isolates, inhibiting 100% of CoNS and S. aureus at MICs ≤ 8 μg/mL and ≤ 4 μg/mL, respectively. MIC 90 values for MRSA were eight-fold higher than those for MSSA isolates (Table 5 ). These results were similar to those previously reported. 7, 15, 16 Although cephalosporins are generally inactive against E. faecalis, ceftobiprole inhibited 88.9% at MICs ≤ 4 μg/mL.
Ceftobiprole showed similar potency to those of 3th-and 4th-generation cephems (MIC 50 values, 0.25 ≥ 16 μg/mL) for the main Enterobacteriaceae species. All cephaloporins demonstrated poor activity against K. pneumoniae (28.9-42.1% susceptible). This fact could be explained by the probable high rate of ESBL-producing K. pneumoniae isolates in Brazilian hospitals and since ceftobiprole is hydrolyzed by class A, B, and D extended-spectrum beta-lactamases, but not by class C enzymes, as previously reported. 17 Ceftobiprole, like cefepime, is a weak inducer and a poor substrate for AmpC β-lactamases. 1, 17 Ceftobiprole like ceftazidime and cefepime (MIC 50/90 ≥ 16 μg/mL, Table 3 ) showed poor in vitro activity against P. aeruginosa and Acinetobacter spp. isolates. Polymyxin was the only antimicrobial agent to show good activity against both P. aeruginosa and Acinetobacter spp. isolates. The elevated carbapenem resistance rates noticed among P. aeruginosa and Acinetobacter spp. tested in this study could be possibly attributed to the spread of clones that produce SPM-1 and OXA-23, respectively, in Brazilian hospitals, as noticed before. 18, 19 Despite the low number of isolates collected, the resistance rates to oxacillin among staphylococci appeared to be similar to those previously reported in a Brazilian study. 3 Curiously, the antimicrobial resistance rates
Ceftobiprole activity against Brazilian isolates observed among Gram-negative bacilli isolates collected from private hospitals were higher than those previously reported by other surveillance studies that evaluated bacterial isolates mostly collected from public/teaching hospitals. 20 There has been a dramatic rise in antibiotic resistance in the hospital setting in the past decade. MRSA and carbapenem-resistant Gram-negative bacilli are of particular concern. 6 There is an urgent need to expand treatment options for treating infections caused by these pathogens. The activity of ceftobiprole against the S. aureus and CoNS isolates studied was good and warrant continued evaluation of ceftobiprole as therapy for severe infections, including skin and soft tissue infections, especially in those institutions/regions where MRSA is highly prevalent.
